---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-010300"
form_type: "8-K"
ticker: "PURE"
cik: "0001006028"
company_name: "PURE BIOSCIENCE, INC."
filed_at: "2024-03-18T23:59:59+00:00"
generated_at: "2026-06-04T14:26:23.684678+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# PURE Bioscience Q2 net product sales $325K, net loss $1.0M; shifting to distributor model

## Summary
- Net product sales $325K in Q2 FY2024, down 18% from $396K YoY; net loss $1.002M vs $1.060M.
- Q2 net loss per share ($0.01); six-month net product sales $1.043M, up 21% from $863K.
- CEO cites unexpected interruption in product flow to one major customer as cause of revenue shortfall.
- Company shifting from direct sales to distributor model to expand market coverage and accelerate growth.
- New food segments and dairy/animal health show interest; registered to exhibit at IAFP July 2024.

## SEC filing metadata
- accession: 0001493152-24-010300
- form_type: 8-K
- ticker: PURE
- cik: 0001006028
- company_name: PURE BIOSCIENCE, INC.
- filed_at: 2024-03-18T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1006028/000149315224010300/0001493152-24-010300-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1006028/000149315224010300/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-010300
- JSON: https://secwatch.observer/filing/0001493152-24-010300.json
- Plain text: https://secwatch.observer/filing/0001493152-24-010300.txt

## Key facts
- Earnings Releases
  PURE BIOSCIENCE, INC. reported the fiscal second quarter ended January 31, 2024 results: revenue $325,000, net income $1,002,000, EPS ($0.01) per share.
  - Period: the fiscal second quarter ended January 31, 2024
  - Revenue: $325,000
  - Net income: $1,002,000
  - EPS: ($0.01) per share
  - Result: reported results
  source text: Net product sales were $325,000 and $396,000 for the fiscal second quarter ended January 31, 2024 and 2023, respectively. The decrease of $71,000 was attributable to decreased sales across our end user network. ● Net loss for the fiscal second quarter ended January 31, 2024 was $1,002,000, compared to $1,060,000 for the fiscal second quarter ended January 31, 2023. ● Net loss, excluding share-based compensation, for the fiscal second quarter ended January 31, 2024 was $938,000, compared to $993,000 for the fiscal second quarter ended January 31, 2023. ● Net loss per share was ($0.01) for the fiscal second quarters ended January 31, 2024 and 2023, respectively.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1006028/000149315224010300/0001493152-24-010300-index.htm
- Earnings Releases
  PURE BIOSCIENCE, INC. reported the six months ended January 31, 2024 results: revenue $1,043,000, net income $1,737,000, EPS ($0.02) per share.
  - Period: the six months ended January 31, 2024
  - Revenue: $1,043,000
  - Net income: $1,737,000
  - EPS: ($0.02) per share
  - Result: reported results
  source text: Net product sales were $1,043,000 and $863,000 for the six months ended January 31, 2024 and 2023, respectively. The increase of $180,000 was attributable to increased sales across our end user and distribution network. ● Net loss for the six months ended January 31, 2024 was $1,737,000, compared to $2,053,000 for the six months ended January 31, 2023. ● Net loss, excluding share-based compensation, for the six months ended January 31, 2024 was $1,593,000, compared to $1,842,000 for the six months ended January 31, 2023. ● Net loss per share was ($0.02) for the six months ended January 31, 2024 and 2023, respectively.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1006028/000149315224010300/0001493152-24-010300-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.